Clinical trials · New Jersey
Metastatic Cancer clinical trials in New Jersey
We’re tracking 146 recruiting metastatic cancer studies with a site in New Jersey — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New Jersey
- NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Hackensack, New JerseyAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Mullica Hill, New JerseyAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Belleville, New JerseyAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Basking Ridge, New JerseyAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Basking Ridge, New JerseyAges 18 years+ - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
East Brunswick, New JerseyAges 18 years+ - NCT06741085RecruitingPhase 2
Radiosurgery plus standard care for lung cancer spread to brain
This trial tests if adding stereotactic radiosurgery (focused radiation) to standard drug therapy is safe and effective for people with EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to improve control of brain metastases while continuing targeted therapy.
Basking Ridge, New JerseyAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
New Brunswick, New JerseyAges 18 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Basking Ridge, New JerseyAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Morristown, New JerseyAges 18 years+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Summit, New JerseyAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Hackensack, New JerseyAges 18 years+ - NCT04862663RecruitingPhase 3
Capivasertib plus hormone therapy for HR+ breast cancer after progression
This Phase 3 trial studies capivasertib (a targeted pill) plus fulvestrant (a hormone injection) together with a CDK4/6 inhibitor to treat HR+ / HER2- advanced breast cancer that has returned or grown despite earlier hormone therapy. It may help by blocking growth signals linked to cancer cell survival.
Camden, New JerseyAges 18–99 - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Hackensack, New JerseyAges 18 years+ - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Freehold, New JerseyAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Belleville, New JerseyAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Hackensack, New JerseyAges 18 years+ - NCT06136624RecruitingPhase 3
Comparing a new drug to standard hormone therapy for advanced prostate cancer
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Morristown, New JerseyAges 18 years+ - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Morristown, New JerseyAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Hackensack, New JerseyAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Hackensack, New JerseyAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Montvale, New JerseyAges 18 years+
Where these studies are running in New Jersey
Institutions with a site for the recruiting metastatic cancer studies listed above.
- Memorial Sloan Kettering Bergen · 7 studies
- Memorial Sloan Kettering Monmouth · 7 studies
- Memorial Sloan Kettering Basking Ridge · 6 studies
- Hackensack University Medical Center · 4 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 4 studies
- Astera Cancer Care · 2 studies
- Atlantic Health System · 2 studies
- AtlantiCare Health Park-Cape May Court House · 2 studies
What taking part in a metastatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Cancer trials in other states
Common questions
- Are there metastatic cancer clinical trials in New Jersey?
- Yes. We're currently tracking 146 recruiting metastatic cancer studies with a site in New Jersey, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic cancer study in New Jersey?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New Jersey to take part?
- Not necessarily. These studies have a site in New Jersey, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic cancer studies open in New Jersey regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.